medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 2

<< Back Next >>

MEDICC Review 2021; 23 (2)

Pretreatment HIV Drug-resistance Surveillance as a Tool for Monitoring: and Control of the HIV/AIDS Epidemic in Cuba

Machado-Zaldívar LY, Blanco-de Armas M, Dubed-Echevarría M, Díaz-Torres HM, López-Rizo LS, Pérez-Guevara MT, Lantero-Abreu MI, Rodríguez-Acosta M

Language: English
References: 24
Page: 64-68
PDF size: 143.20 Kb.


ABSTRACT

The HIV/AIDS epidemic is an ongoing threat to public health. Its elimination requires greater efforts to broaden antiretroviral treatment coverage, availability and personalization. HIV drug resistance is currently a global problem due to its continuing increase in recent years, undermining effi cacy of antiretroviral therapy. Pretreatment HIV drugresistance surveillance is part of WHO’s strategy for addressing antiretroviral drug resistance.
This paper describes and analyzes pretreatment HIV drug-resistance surveillance in Cuba. It presents a chronology of HIV resistance studies in untreated patients, along with their results and programmatic actions related to fi rst- and second-line treatment regimens. Cuba’s incorporation into the Global HIV Drug Resistance Surveillance Laboratories Network and the advantages of having a WHO-designated laboratory in which to conduct periodic studies of HIV drug-resistance surveillance are described.
HIV drug-resistance surveillance in Cuba is a necessary tool in HIV/ AIDS monitoring and control, as it obtains population-scale data used to inform programmatic decisions related to optimizing fi rst- and second-line treatments for children and adults, as well as helping meet goals of eliminating HIV transmission.


REFERENCES

  1. Tang MW, Shafer RW. HIV antiretroviral resistance.Scientifi c principles and clinical applications.Drug. 2012 Jun 18;72(9):e1–e25.

  2. Clutter DS, Jordan MR, Bertagnolio S, ShaferRW. HIV-1 drug resistance and resistance testing.Infect Genet Evol. 2016 Dec;46:292–307.

  3. World Health Organization. Surveillance of HIVdrug resistance in populations initiating antiretroviraltherapy (pre-treatment HIV drug resistance).Concept note. Geneva: World Health Organization;2014 Mar. 36 p. ISBN 978 92 4 1507 196.English, French.

  4. World Health Organization. Global action plan onHIV drug resistance 2017-2021. Geneva: WorldHealth Organization; 2017. p. 1–37.

  5. Ministry of Public Health (CU). Plan EstratégicoNacional para la Prevención y el Control de lasITS y el VIH/SIDA. 2014-2018. Havana: Ministryof Public Health (CU); 2015. ISBN: 978-959-283-115-5. Spanish.

  6. Ministry of Public Health (CU). Plan EstratégicoNacional para la prevención y el control de lasITS, el VIH y las hepatitis. 2019-2023. Havana:Ministry of Public Health (CU); 2019. ISBN: 978-959-283-180-3. Spanish.

  7. Rolo F, Miranda L, Wainberg MA, Gu Z, LobainaL, Noa E, et al. Envelope V3 Region Sequencesof Cuban HIV-1 Isolates. J Acquir Immune Defi cSyndr Hum Retrovirol. 1995 Jun 1;9(2):123–5.

  8. Cuevas MT, Ruibal I, Villahermosa ML, Díaz H,Delgado E, Vázquez-de Parga E, et al. HighHIV-1 genetic diversity in Cuba. AIDS. 2002 Aug16;16(12):1643–53.

  9. Blanco-de Armas M, Machado-Zaldívar LY, DíazH, Ruiz N, Romay-Franch D, Silva E. HIV-1genetic variability in Cuba and implications fortransmission and clinical progression. MEDICCRev. 2015 Oct;17(4):25–31.

  10. Ruibal-Brunet I, Cuevas MT, Díaz-Torres H, VillahermosaML, Noa-Romero E, Vázquez de PargaE, et al. Genotypic resistance mutations to antiretroviraldrugs in HIV-1 B and non-B subtypesfrom Cuba. Rev Panam Salud Pública. 2001Sep;10(3):174–80.

  11. Collazo Herrera M, Pérez Ávila J, TápanesPeraza R, Pérez Correa D, Martínez RodríguezA, Castro Peraza O, et al. Impacto económicosocialde la terapia antirretroviral de producciónnacional para el VIH/SIDA en Cuba. PharmacoeconSpan Res Artic. 2009;6:1–12. Spanish.

  12. Pérez L, Pérez Álvarez L, Carmona R, AragonésC, Delgado E, Thomson MM, et al. Genotypicresistance to antiretroviral drug in patientsinfected with several HIV type I genetic forms in Cuba. AIDS Res Hum Retroviruses. 2007Mar;23(3):407–14.

  13. Pérez L, Kourí V, Alemán Y, Abrahantes Y, CorreaC, Aragonés C, et al. Antiretroviral drug resistancein HIV-1 therapy-naive patients in Cuba.Infect Genet Evol. 2013 Jun;16:144–50.

  14. Alemán-Campos Y, Kourí-Cordellá V, Pérez-Santos L, Fonseca-Gómez C, Pérez-Ávila J,Ortega-González LM, et al. HIV-1 antiretroviralresistance in Cuba: 2009–2014. MEDICC Rev.2018 Jul;20(3):15–21.

  15. Machado LY, Dubed M, Díaz H, Ruiz N, RomayD, Valdés N, et al. Transmitted HIV type 1drug resistance in newly diagnosed Cubanpatients. AIDS Res Hum Retroviruses. 2013Feb;29(2):411–4.

  16. Machado LY, Díaz H, Blanco M, Dubed M, RuizN, Martínez L, et al. Emergence of the transmittedresistance of HIV-1 to antiretroviral drugs inCuban patients during the period 2009-2016.J Internat AIDS Soc. 2018 Apr 19;21(Suppl3):e25093.

  17. Machado LY, Blanco M, López LS, Díaz HM,Dubed M, Valdés N, et al. National survey of pretreatmentHIV drug resistance in Cuban patients.PLoS One [Internet]. 2019 Sep 3 [cited 2020 Sep26];14(9):e0221879. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719847/

  18. Lapadula G, Izzo I, Gargiulo F, Paraninfo G,Castelnuovo F, Quiros-Roldan E, et al. Updatedprevalence of genotypic resistance amongHIV-1 positive patients naïve to antiretroviraltherapy: a single center analysis. J Med Virol.2008;80(5):747–53.

  19. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Publications.Overview. Guidelines on the public healthresponse to pre-treatment HIV drug resistance; 2017 Jul 1 [cited 2020 Sep 26]. 84 p. Available at:https://www.who.int/publications/i/item/9789241550055

  20. World Health Organization. Update of recommendationson fi rst-and second line antiretroviralregimens 2019. Geneva: World Health Organization;2019 (WHO/CDS/HIV/19.15) License: CCBY-NC-SA 3.0. IGO.

  21. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Centro dePrensa. La OMS valida la eliminación de Cubade la transmisión de madre a hijo del VIH y dela sífi lis (comunicado de prensa); 2015 Jun 30[cited 2020 Sep 26]. Available at: http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/es/. Spanish.

  22. UNAIDS [Internet]. Geneva: UNAIDS;c2021. Nuestra Acción. 90-90-90: Tratamientopara todos; [cited 2020 Sep 26].Available at: https://www.onusida.org/es/resources/909090. Spanish.

  23. World Health Organization/HIVResNet DrugResistance Laboratory Strategy. Antivir Ther.2008 Apr;13 Suppl 2:49–57.

  24. World Health Organization. HIV drug resistancereport 2019. (WHO/CDS/HIV/19.21) License:CC BY-NC-SA 3.0. IGO. Geneva: World HealthOrganization; 2019.




2020     |     www.medigraphic.com